The Germany Pharmaceuticals Market size is expected to reach USD 65.9 billion by 2027, expanding at a CAGR of 6.0%, according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of acute and chronic diseases and increasing R&D expenditure by pharmaceutical companies are expected to drive the market.
Furthermore, rising clinical trials and approval of novel
immune-suppressive therapies are anticipated to propel market growth. For
instance, in June 2020, Sandoz International GmbH launched Dailiport capsules
(generic tacrolimus) in Germany and other European countries. Dailiport
capsules are indicated for adult kidney and liver transplant patients.
In addition, the export of pharmaceutical products by
pharmaceutical companies in Germany to various countries is expected to fuel
market growth. For instance, according to Germany Trade and Invest, in China,
22.0% of imported pharmaceutical products are from German companies.
Key players entering into strategic initiatives such as
partnership, licensing, acquisition, and collaboration to expand and strengthen
their regional presence is expected to boost the market growth. For instance,
in November 2019, Bristol-Myers Squibb Company acquired Celgene Corporation.
This acquisition was aimed at helping the company expand its oncology portfolio
worldwide and develop innovative medicines.
In addition, rising funds by organizations for the
development of pipeline drugs are anticipated to accelerate market growth. For
instance, in January 2019, Atriva Therapeutics GmbH closed its series A
financing led by Meneldor and High-Tech Gründerfonds GmbH (HTGF) for its lead
drug candidate ATR-002. This drug candidate is developed against influenza infection
and other respiratory infections.
Various other organizations, such as the European Cancer
Organisation (ECCO), European Cancer Patient Coalition (ECPC), and European
Organisation for Research and Treatment of Cancer (EORTC) provide funds for
cancer research programs and treatment plans.
Furthermore, increasing the availability of generic drugs at
a lower price is expected to boost the market growth. For instance, in July
2019, Sandoz of Novartis AG launched a generic version of gefitinib for locally
advanced or metastatic NSCLC. The launch of the generic version is estimated to
increase the number of patients treated due to the favorable cost of the drug.
List of Key Players of Germany Pharmaceuticals Market
- Boehringer
Ingelheim International GmbH
- Bayer
AG
- Merck
& Co., Inc.
- Fresenius
Kabi AG
- STADA
Arzneimittel AG
- Pfizer
Inc.
- Abbott
- Abbvie
Inc.
- Teva
Pharmaceutical Industries Ltd.
- Novartis
AG
- Sanofi
- Johnson
& Johnson Services, Inc.
- GlaxoSmithKline
plc
- AstraZeneca
- Celgene
Corporation
- Amgen
Inc.
- Novo
Nordisk A/S
- Eli
Lilly and Company
- Allergan
Request a free sample
copy or view report summary: Germany Pharmaceuticals Market Report
Germany Pharmaceuticals Market Report Highlights
- In
2019, anti-cancer was the largest-revenue holding drug class in the market
owing to rising approval of new drugs and increasing research studies on
new approaches to treating various cancers
- Immunosuppressant
product type is estimated to be the fastest-growing drug class during the
forecast period owing to rising development and launch of novel
immunosuppressant
- Oncology
application held the largest revenue share in 2019 due to the increasing
prevalence of breast cancer, prostate cancer, and lung cancer
- On the
basis of type, the generic drugs segment is expected to be the
fastest-growing segment over the forecast period due to its
cost-effectiveness and expiration of patents.
Germany Pharmaceuticals Market Segmentation
Grand View Research has segmented the Germany
pharmaceuticals market on the basis of drug class, application, type, and
formulation:
Germany Pharmaceuticals Drug Class Outlook (Revenue, USD
Million, 2016 - 2027)
- Anti-cancer
- Anti-diabetics
- Anti-rheumatics
- Vaccines
- Anti-viral
- Immunosuppressant
- Bronchodilators
- Dermatological
- Anti-hypertensive
- Others
Germany Pharmaceuticals Application Outlook (Revenue, USD
Million, 2016 - 2027)
- Oncology
- Breast
cancer
- Lung
cancer
- Colorectal
cancer
- Ovarian
cancer
- Prostate
cancer
- Others
- Infectious
Diseases
- Cardiovascular
Diseases
- Central
Nervous System Disorders
- Immunological
Disorders
- Metabolic
Disorders
- Gastrointestinal
Disorders
- Respiratory
Diseases
- Ophthalmology
- Dermatology
Disorders
- Others
Germany Pharmaceuticals Type Outlook (Revenue, USD
Million, 2016 - 2027)
- Branded
- Generics
Germany Pharmaceuticals Formulation Outlook (Revenue, USD
Million, 2016 - 2027)
- Solid
formulation
- Tablets
- Capsules
- Others
- Liquid
& semi-liquid formulation
- Oral
- Topical
- Sublingual
and buccal
- Rectal
- Parenteral
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment